Session Notes: Start with Why? Ice-Breaker Session
Executive Summary
This ice-breaker session revealed that funding constraints and data complexity are the dominant challenges facing pharmaceutical professionals over the next two years. While participants came seeking AI best practices and networking opportunities, they identified a critical paradox where increased data availability is actually complicating rather than improving decision-making. The session highlighted ongoing struggles with organizational change management as companies attempt to balance agile methodologies with traditional stakeholder expectations.
Full Notes
Conference Motivations and Networking Focus
Participants entered the session with diverse but aligned motivations, prominently featuring networking and learning as primary drivers. The interactive format immediately revealed strong interest in AI applications, with 'best use of AI' emerging as a key agenda item. Customer and patient needs also featured prominently, indicating a continued focus on end-user value creation. The emphasis on networking was particularly notable, suggesting that peer-to-peer knowledge exchange remains critical in an industry facing rapid transformation. This aligns with the broader conference theme of practical, stakeholder-driven insights rather than theoretical approaches.
Funding and Resource Constraints
The most consistent theme emerging from participant input was financial pressure, with funding identified as the biggest challenge across organizations. This reflects the broader industry context where drug price pressures are intensifying while success rates remain uncertain. Participants described an environment where 'money is getting tighter' and everyone is demanding more from molecule development programs. The challenge extends beyond simple budget cuts to fundamental questions about resource allocation and efficiency. Organizations are being forced to demonstrate greater value with fewer resources, creating pressure for more strategic portfolio management and operational excellence.
The Data Complexity Paradox
A surprising insight emerged around data management, where participants revealed that increased data availability is creating rather than solving problems. The session facilitator captured this perfectly: while teams collect more data expecting better decisions, the complexity is becoming overwhelming. Some participants admitted feeling 'outmanaged' by the sheer volume of information requiring processing. This represents a significant shift from the historical challenge of data scarcity to one of data overwhelm, requiring new frameworks for information synthesis and decision-making. The challenge isn't technical capability but organizational capacity to extract actionable insights from complex datasets.
Change Management and Organizational Resistance
The discussion revealed ongoing tensions between traditional and agile approaches within pharmaceutical organizations. While some teams have embraced agile methodologies, significant resistance persists from stakeholders accustomed to conventional reporting structures. This creates a dual challenge: implementing new operational models while managing stakeholder expectations formed by decades of traditional approaches. The 'old system versus new system' conflict extends beyond process changes to fundamental questions about how organizations make decisions, allocate resources, and measure success. Time-to-market pressures compound these challenges, creating urgency around transformation while maintaining operational stability.
Key Insights (10)
Money and efficiency dominate concerns
Data complexity paradox emerging
AI integration accelerating
Agile transformation still incomplete
Funding pressure drives efficiency demands
Data overwhelm replacing data scarcity
Change management resistance persists
Data complexity challenge
Industry environment assessment
Interactive discussion format
Full Transcript (click to expand)
[0:02] : The pressure on drug prices is increasing. Success rates are even more unsure, and everyone is demanding more on molecules their development. Seems the space is not getting easier. However, we are already in there. So we jumped ahead. the Euro saying, well, great, so let's be interactive. And thank you all. We are already interactive, and you're giving me your feedback. Why are we here? I see the networking big up there, and I'm very glad for that because it's definitely my focus: networking and learning. Best use of AI. AI definitely on the agenda. So that's very good. [1:03] : Customer needs, patient needs. So a lot of diverse topics. Wonderful. Meet and greet people. I give you still a minute and we can save it. No, we have it then for the next day still. It's kind of fixed. Two more? Perfect. Let's move to the next question. So this is why we are at the conference. Next question. What is the biggest challenge in the next two years? Either in your job or your organization or in the pharma world? It seems funding is a huge part. It goes back to money is getting tighter. [2:38] : Fast moving, definitely also AI. Simplification, everyone was collecting more data. And while we think we should make better decisions with more data, it also increases a level of complexity. We are not always sure we can manage, at least I sometimes feel outmanaged. That's very cool. Change management, fast moving. AI, funding, time to market this into financing. So what is the challenge when you all go back to your place? Like the hippo rule, we can total on that one. of resources going back to finance, financing. To what we've seen before. [4:43] : It's about money being more efficient dealing with the amount of data to make good decisions. Drive our leaders to accept maybe deep data in different ways. On the one side, I'm not sure who has already agile organizations introduced. And then there's still people pushing for the old system. Stakeholder management reporting. So we still have 10 minutes before Kamil will start talking. And I would love to use them for a discussion at the table, maybe even talking to someone on the table you do. [5:38] : don't know to bring in the networking and share a bit of your day-to-day challenges and what you hope to learn from the conference of take back. This be a good thing for 10 minutes or I have ten minutes. That's perfect. So because they're always like there are returning parts now, so I already let you know them. But for example, it's uh lumber screw to find out uh speaker several crop just to sort of speak more external part. Yeah, so they sort of so that's not just a random thing happening. [7:16] : Yeah, like because they actually copy all of the information from harm, but there are still carriers enough so as things that's kind of the theme talk as well as well. Like exactly. Yeah, to do and then they're like more more open to like to try and have it and incorporate it into data. Yeah. It is a very it's very good. Yeah. I think it's a tweak that kind of like simplifying things. Yeah, and that's I mean that's a good goal also. [7:59] : So yeah, trying to get uh everyone to sign in and then still get exactly their attention like what what is that actually that's pretty good. Sure, we can not already slowness. pointer you have to use absolute. my estimate and the picking on the same. necessarily it's more spectrum. So it started to play this. But I I understand uh it's fast. say this is that. Yeah. Okay, so Yeah. Okay, possibly.